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A B S T R A C T   
The administration of extracellular vesicles (EV) from mesenchymal stromal cells (MSC) is a promising cell-free 
nanotherapy for tissue repair after myocardial infarction (MI). However, the optimal EV delivery strategy re-
mains undetermined. Here, we designed a novel MSC-EV delivery, using 3D scaffolds engineered from decel-
lularised cardiac tissue as a cell-free product for cardiac repair. EV from porcine cardiac adipose tissue-derived 
MSC (cATMSC) were purified by size exclusion chromatography (SEC), functionally analysed and loaded to 
scaffolds. cATMSC-EV markedly reduced polyclonal proliferation and pro-inflammatory cytokines production 
(IFNγ, TNFα, IL12p40) of allogeneic PBMC. Moreover, cATMSC-EV recruited outgrowth endothelial cells (OEC) 
and allogeneic MSC, and promoted angiogenesis. Fluorescently labelled cATMSC-EV were mixed with peptide 
hydrogel, and were successfully retained in decellularised scaffolds. Then, cATMSC-EV-embedded pericardial 
scaffolds were administered in vivo over the ischemic myocardium in a pig model of MI. Six days from im-
plantation, the engineered scaffold efficiently integrated into the post-infarcted myocardium. cATMSC-EV were 
detected within the construct and MI core, and promoted an increase in vascular density and reduction in 
macrophage and T cell infiltration within the damaged myocardium. The confined administration of multi-
functional MSC-EV within an engineered pericardial scaffold ensures local EV dosage and release, and generates 
a vascularised bioactive niche for cell recruitment, engraftment and modulation of short-term post-ischemic 
inflammation.  
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1. Introduction 
Ischaemic heart disease, including myocardial infarction (MI), is the 
main cause of morbidity and mortality for both men and women 
worldwide [1]. The myocardial injury caused by MI triggers an in-
flammatory reaction, extending myocardial damage but also a prereq-
uisite to transition toward myocardial healing and scar formation. The 
extent of the non-contractile scar formed would determine the proclivity 
to adverse cardiac remodelling, cardiac malfunction and, ultimately, 
overt heart failure [2]. The current best treatment for heart failure is 
heart transplantation, but the great demand for organs generated by the 
growing epidemic of cardiac-related diseases is presently unmet [3,4]. 
This urges therapies focused on preserving cardiac function after injury, 
such as cell-based therapies and tissue engineering approaches aimed at 
modulating post-MI inflammation to mitigate myocardial scarring [5]. 
For that purpose, the administration of mesenchymal stromal cells 
(MSC) has been studied to promote healing of ischaemia-injured tissue 
given their immunomodulatory and regenerative capabilities [6–9]. In 
this context, our laboratory was the first to pose attention to a popula-
tion of cardiac adipose tissue-derived MSC (cATMSC) which, despite 
residing in an adipocytic environment, do not differentiate into adipo-
cytes but acquire de novo cardiac and endothelial markers in vitro (both 
human and porcine cells), and contribute to myocardial tissue revas-
cularisation and infarct size reduction in vivo [6,7,10,11]. Moreover, 
their combination with decellularized cardiac tissue as natural 
three-dimensional (3D) scaffolds is a promising tissue engineering 
strategy to locally deliver MSC and enhance their therapeutic effect to 
restore cardiac function after MI [7,10,12,13]. In pre-clinical studies, 
these engineered cardiac grafts have significantly improved ventricular 
function, showing scaffold integration with the underlying myocardium, 
and induced neovascularization and innervation [12,13]. Nevertheless, 
scarcely any cell grafted into the host myocardium. 
At the same time, the current deficits understanding the mechanistic 
action of cell therapy for cardiac repair and regeneration limits its po-
tential, optimization, and clinical implementation [14]. Numerous evi-
dences suggest that MSC may promote MI healing thanks to the secretion 
of various soluble factors that boost endogenous repair in a paracrine 
manner, rather than replicating and differentiating themselves [15,16]. 
Amongst them, there is growing interest in MSC’s release of extracellular 
vesicles (EV), a variety of lipid bilayered nanovesicles having the bio-
logical characteristics of the originating cells, and containing a plethora 
of functional lipids, RNA, and proteins [17]. EV can transfer these 
bioactive molecules, and thus are valuable mediators of in intercellular 
communication. In this context, we corroborated EV as functional 
players of the paracrine immunosuppressive capability of MSC [18]. 
However, the mode of action of EV and the optimal administration route 
to enable sufficient EV dose to be locally active remain unknown. 
In the present study, we explored the anti-inflammatory and healing 
effects of porcine MSC-EV, unravelling a new role of MSC-EV as re-
cruiters of endogenous pro-angiogenic cells, and developed novel po-
tency assays for porcine MSC-EV. Also, we designed a new method for 
the local delivery of multifunctional MSC-EV over the ischemic 
myocardium in a pig model of MI, by using a 3D-bioengineered scaffold 
showing high EV-embedding capacity, local release and modulation of 
post-ischemic inflammation in vivo. 
2. Materials and methods 
2.1. Porcine cardiac adipose tissue-derived MSC isolation and culture 
Primary porcine cATMSC were obtained from pigs (Large White ×
Landrace) undergoing cardiac surgery (n = 39) by cardiac adipose bi-
opsy (1.63 ± 0.69 g), as previously described [7]. Tissue samples were 
washed from debris and red blood cells in phosphate-buffered saline 
(PBS; Oxoid), and digested for 30 min with 0.05% collagenase (Type II; 
Gibco Invitrogen Corp.) at 37 ◦C under mild shaking. Digestion was 
quenched with α-MEM (Sigma Aldrich) supplemented with 10% 
heat-inactivated foetal bovine serum (FBS), 2 mM L-glutamine, 1% 
penicillin-streptomycin (P/S) (all from Gibco Invitrogen Corp.) and 5 
μg/ml Plasmocin™ (Invivogen) (α-MEM-FBS). Cells were then centri-
fuged at 1200×g for 10 min and cultured by adherence in α-MEM-FBS at 
37 ◦C 5% CO2. The purity of established cell cultures was analysed at 
passages 4–8 by immunostaining with monoclonal antibodies against 
CD105 (Abcam), CD44, CD45, CD14 (AbD Serotec), CD29, CD34, CD90 
and CD106 or IgG isotype control (BD Pharmingen) using a FACSCanto 
II flow cytometer (BDBiosciencies) and the FACSDiva™ software (BD 
Biosciencies). 
2.2. Extracellular vesicle production and isolation 
EV were produced and isolated as previously published [18,19]. All 
relevant data regarding our experiments have been submitted to the 
EV-TRACK knowledgebase (EV-TRACK ID: EV200061) [20]. 
Serum-derived bovine EV were depleted by ultracentrifuging 2 ×
α-MEM-FBS at 100,000×g for >16 h (TH641 rotor, adjusted k-Factor =
240.82) in a Sorvall WX Ultra 100 Series ultracentrifuge (Thermo Fisher 
Scientific). The supernatant was filtered through 0.22-μm (Sarstedt) for 
sterilization, and diluted to a 1 × working solution with α-MEM 
medium. 
For EV production, the culture media of two T-175 flasks of porcine 
cATMSC grown to confluence was replaced by 15 mL each of EV- 
depleted α-MEM-FBS. After 48 h of culture, the conditioned medium 
was harvested and centrifuged at 400×g for 5 min and 2000×g for 10 
min to exclude cells and debris, respectively. Cells were counted at time 
of EV harvesting (~1 × 107), and cell viability was >95% (trypan blue 
staining). The cleared supernatant was then centrifuged at 2000×g for 
35 min through a 100-kDa ultrafiltration device (Amicon Ultra centrif-
ugal filter; Millipore) to obtain concentrated conditioned medium 
(CCM). 
EV were then purified from the CCM by size-exclusion chromatog-
raphy (SEC) following our already published method [18,21,22]. 
Briefly, the SEC column was prepared packing 12 mL of Sepharose CL-2B 
(Sigma Aldrich) into a sterilized Puriflash dry load 12G flash column 
(Interchim-Cromlab). Then, 500 μL CCM were loaded into the column 
and eluted with sterile 10% sucrose (w/v; Sigma Aldrich) as an elution 
buffer, collecting 500-μL fractions immediately after loading. Protein 
elution was monitored by 280 nm absorbance (Nanodrop spectropho-
tometer; Thermo Fisher Scientific) or using the Pierce BCA Protein Assay 
kit (ThermoFisher), interpolating to a Bovine Serum Albumin (BSA; 
Sigma Aldrich) standard curve. Bead-based flow cytometry was 
routinely performed to pool together the CD44+CD63+ EV-containing 
fractions (EV pool) for use in further experiments. 
2.3. Bead-based flow cytometry 
Porcine cATMSC-EV were identified by bead-based flow cytometry, 
screening for EV and MSC markers. EV were covalently coupled to 4-μm 
aldehyde/sulphate-latex beads (Invitrogen-ThermoFisher Scientific) 
with a 15 min incubation, and then blocked for 2 h with BCB buffer (PBS, 
0.1% BSA, and 0.01% sodium azide (NaN3); Sigma Aldrich). EV-coupled 
beads were centrifuged at 2000×g for 10 min and re-suspended in BCB 
buffer. Next, beads were incubated for 30 min at RT with the 
fluorochrome-conjugated antibodies anti-CD73-PE and anti-CD90-PE- 
Cy7 (1:50; both from BD); or the primary Ab anti-CD9 (Clone VJ1/20; 
1:10), anti-CD63 (Clone TEA3/18; 1:10), anti-CD81 (Clone 5A6; 1:10), 
anti-CD29 (1:10; BD), anti-CD44 (1:10; AbD Serotec) or IgG isotype 
control (1:10; Abcam) followed by incubation with the FITC-goat F(ab’) 
2 anti-mouse IgG (1:10; Bionova) or A488-rabbit anti-rat IgG (1:100; 
AbD Serotec). EV-coupled beads were washed with BCB buffer and spun 
down at 2000×g for 10 min after each step. Data was acquired in a 
FACSVerse flow cytometer (BD), and analysed with FlowJo® v10 (BD). 
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2.4. Cryo-electron microscopy 
EV size and morphology were examined by cryo-transmission elec-
tron microscopy (cryo-EM) as previously detailed [18]. 
2.5. Nanoparticle tracking analysis 
Size distribution and particle concentration was analysed in a 
NanoSight LM10-12 instrument (Malvern Instruments Ltd), with NTA 
software (version 3.1, build 3.1.46) averaging three videos of 60 s at 30 
FPS, with a camera level of 16, and manual control of temperature (21- 
25 ◦C) of samples diluted to 20–120 particles/frame, as previously re-
ported [18]. 
2.6. EV staining 
Fluorescently-labelled EV were produced by staining EV-secreting 
cATMSC with the lipophilic dyes NIR815 (excitation/emission 786/ 
815 nm; Thermo Fisher Scientific) or PKH26 (excitation/emission 551/ 
567 nm; Sigma Aldrich) following manufacturers’ instructions. Fluo-
rescently labelled cells were washed with PBS, cultured in α-MEM-FBS 
and then changed to EV-depleted medium to produce fluorescently- 
labelled EV, which were isolated from the conditioned medium using 
the already described methodology. 
2.7. Endotoxin detection 
The endotoxin concentration of cATMSC-EV preparations was 
determined using the Pierce Chromogenic Endotoxin Quant Kit (Ther-
moFisher) following the manufacturer’s instructions. Briefly, the endo-
toxin concentration was determined for EV at 1 × 106 cATMSC/ml in a 
Limulus Amebocyte Lysate (LAL)-based chromogenic reaction using an 
E. coli (011:B4) endotoxin standard curve and analysing different sample 
dilutions. The absence of LAL inhibition was confirmed in endotoxin 
spike-in reaction. 
2.8. Porcine peripheral blood mononuclear cells isolation and functional 
assays 
Peripheral blood mononuclear cells (PBMC) were obtained by Ficoll 
density gradient centrifugation (BD) of fresh whole blood samples (10- 
mL EDTA tubes; BD) from Landrace × Large White pigs (30–35 kg; 
indistinct sex). After harvesting, PBMC were counted and frozen. To 
monitor proliferation, thawed PBMC were labelled with Violet Cell-
Trace™ dye (Thermo Fisher Scientific) following manufacturer’s pro-
tocol. Then, PBMC were seeded in 96-well plates at 1 × 105/well; 100 μl 
final volume of serum-free X–VIVO 15 media (Lonza) complemented 
with 2 mM L-glutamine and 1% P/S. 
PBMCs were stimulated with 0.6 ng/mL PMA (phorbol 12-myristate 
13-acetate; Sigma Aldrich) and 200 ng/mL ionomycin (Io; Sigma 
Aldrich), in the presence or not of cATMSC-EV (pool of three cATMSC 
donors), at the indicated ratios according to EV-producing cell equiva-
lents (1 × 106/well, 2 × 105/well, 1 × 105/well or 4 × 105/well). After 5 
days of culture, supernatants were collected and frozen for downstream 
cytokine production analysis, and the number of FSChighVioletlow 
proliferating cells was assessed by flow cytometry with an LSRFortessa 
(BD) and FlowJo® v10 software. 
Alternatively, 1 × 105 PBMC were cultured together with cardiac 
scaffolds (7.1 mm2) filled with peptide hydrogel and either cATMSC-EV 
(1 ×106 EV-producing cells/scaffold) or 10% sucrose buffer. After 5 days 
of culture, supernatants were harvested for cytokine production analysis. 
2.9. Cytokine response 
The levels of IL1β, IL4, IL6, IL8, IL10, IL12p40, IFNα, IFNγ, and TNFα 
were measured in the supernatants of cultured PBMC using the Cytokine 
& Chemokine 9-Plex Porcine ProcartaPlex™ Panel 1 immunoassay 
(Invitrogen-ThermoFisher Scientific) in a Luminex 200 Instrument, and 
analysed with the xPONENT software (build 3.1.971.0) following 
manufacturers’ instructions. 
2.10. Porcine outgrowing endothelial progenitor cell cultures and 
characterization 
Outgrowing colonies from endothelial progenitor cell cultures were 
isolated by processing fresh 20-mL venous blood samples (<2 h) from 
pigs (Landrace × Large White; 30–35 kg; indistinct sex) by Ficoll 
gradient (GE Healthcare) as previously described [23]. Remaining 
erythrocytes were removed with lysis buffer (155 mM NH4Cl, 10 mM 
NaHCO3, and 0.115 mM EDTA), PBMC were re-suspended in endothelial 
growth medium-2 (EGM-2; Clonetics®), seeded at 2 × 107 cells/mL in 
fibronectin-coated plates (10 μg/mL; Sigma-Aldrich), and cultured with 
media replacement every 2–3 days. Late outgrowth endothelial cell 
(OEC) colonies with clonogenic capacity were visible after 14 days in 
culture, further expanded and frozen in liquid nitrogen until further use. 
OEC immunophenotyping was performed by fixing cells with 4% 
paraformaldehyde (Sigma Aldrich) for 15 min, washing with 0.1% 
Tween-PBS (T-PBS), blocking for 1 h (1% BSA in T-PBS), and then 
incubating at 4 ◦C for 16 h with the primary antibodies anti-VEGFR2 
(1:50; Santa Cruz Biotechnology), anti-CD31 (1:50; Abcam), and anti- 
vWF (1:100; Sigma Aldrich). After washing with T-PBS, cells were 
incubated with the secondary antibodies AlexaFluor® 488 and Alexa-
Fluor® 568 (1:1000; Invitrogen) for 1 h at RT and counterstained with 
Vectashield® mounting medium with DAPI (Vector Laboratories, Inc.) 
prior to visualization in an Olympus BX61 microscope (Olympus). 
Alternatively, OEC were blocked with 25% AB human serum (Sigma- 
Aldrich) in 1% BSA and 0.1% NaN3 in PBS for 15 min at RT, and labelled 
with anti-CD34-PE (BD) for 30 min at RT. After washing and filtering 
through a 30-μm filter (Partec), cells were analysed in a FACSAria flow 
cytometer (BD) to confirm their hematopoietic/progenitor origin. 
The capacity of OEC to form vessel-like structures was evaluated in 
an in vitro Matrigel assay. 200 μL of ice-cold Matrigel™ (growth factor- 
reduced; BD) was placed in 24-well plates and incubated at 37 ◦C for 30 
min. Then, 4 × 104 OEC were seeded in EGM-2. After 24 h, images were 
taken using the Olympus IX71 microscope (Olympus). 
2.11. Migration assay 
Cell migration driven by EV was measured in agarose spots using an 
adaptation of a previously published protocol [24,25]. Beforehand, 
wells dedicated to OEC were coated with 10 μg/mL fibronectin (Bio-
chrom) and left dry. In each quadrant drawn in wells of 6-well plates, we 
placed three 5-μL droplets of 0.5% low-melting-point agarose (40 ◦C, 
Ecogen) mixed 1:1 (v/v) with either 10% sucrose, vascular endothelial 
growth factor (VEGF; 50 ng/mL final concentration; Sigma Aldrich), or 
cATMEC-EV (8 × 104 or 4 × 104/spot). The plates were placed at 4 ◦C for 
15 min to promote gel solidification and spot adherence to the plate 
surface. Next, either cATMSC in α-MEM-FBS or OEC in EGM-2 complete 
medium (10% FBS), were poured into the corresponding wells and 
allowed to seed for 3 h at 37 ◦C. To limit cell proliferation and favour 
chemoattractant detection by cells, culture media was replaced with low 
serum supplemented medium (0.2% FBS). 
Localizations of the border of the agarose spots were randomly 
picked to take pictures (3 × 3 mosaic at 20 × objective) every hour for 
21 h with an Axioskop Z1 microscope (Zeiss), under controlled tem-
perature and CO2 level. We compiled the images to videos, and random 
cells were followed using the Manual tracking plug-in Fiji software 
(Image J 1.54w, NIH) and the Chemotaxis and Migration tool software 
version 2.0 (Ibidi, Inc.) to quantify distance, velocity, and directionality 
of cell movement. 
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2.12. Tube formation assay 
OEC tube formation capacity was measured in 24-well plates pre- 
coated with 200 μL/well of ice-cold Matrigel (Corning). OEC (2 × 104 
cells/well) were seeded in complete EGM-2 media without VEGF 
(Lonza) in the presence of cATMSC-EV (2 × 106/ml, 1 × 106/ml or 4 ×
105/ml EV-producing cells), or VEGF (200 ng/mL; R&D systems) as a 
positive control. Cells were incubated for 6 h at 37 ◦C 5% CO2 and im-
ages were taken with a phase contrast inverted microscope at 10 ×
objective magnifications and analysed using the Fiji (ImageJ) Angio-
genesis Analyser plugin. 
2.13. Generation of cardiac scaffolds 
Cardiac scaffolds were generated by decellularisation of either 
human pericardial or porcine myocardial tissues. The formers were 19 
healthy pericardial samples from patients (n = 19; 16 males, 3 females; 
mean age, 65 ± 12 years; range, 44–85 years) who were undergoing 
cardiac interventions at our hospital, and who had given their signed 
consent. The local ethics committee revised and approved this study, 
whose protocols conformed to the principles outlined in the Declaration 
of Helsinki. Additionally, we used a total of 21 myocardial scaffolds 
obtained from porcine heart left ventricles from a slaughterhouse 
(Landrace × Large White pigs; n = 4). 
We proceeded with a detergent-based decellularisation (SDS and 
Triton X-100) of either cardiac tissue, followed by DNase I treatment, 
lyophilisation, and sterilization as previously detailed by our group [7, 
26]. Scaffold size was standardised to 7.1 mm2 and 50.3 mm2 using 
disposable 3-mm and 8-mm biopsy punches respectively, or to 2 cm2 by 
using a scalpel. 
2.14. EV delivery into decellularised scaffolds 
The EV pool, corresponding to a specified number of producing 
cATMSC, was concentrated with a sterile 2-mL 100-kDa ultrafiltration 
device (Merck Millipore) to adjust its final volume according to the size 
of the intended scaffold, using 10% sucrose buffer (see Fig. S5). Adjusted 
EV volume was then mixed (1:1, v/v) with 0.3% PuraMatrix® self- 
assembling peptide hydrogel (Corning) in 10% sucrose, and this 
mixture was laid over the lyophilised, decellularised scaffolds to both 
rehydrate and fill the scaffolds with EV. As control, 10% sucrose buffer 
was mixed (1:1, v/v) with the peptide hydrogel. Specifically, a 4.2 μl mix 
(containing hydrogel and cATMSC-EV from 1 × 106 EV-producing cells) 
was added to 3-mm ∅ scaffolds and used to analyse its influence on 
allogeneic PBMC cytokine response; a 100 μl mix (containing hydrogel 
and cATMSC-EV from either 1 × 105 or 1 × 106 EV-producing cells, 
previously stained with either NIR815 or PKH26) was added to 8-mm ∅ 
scaffolds to assess EV retention by NIR815-EV scanning, PKH26-EV 
confocal microscopy analysis or by scanning electron microscopy 
(SEM); and a 200 μl mix (containing hydrogel and EV from 20 × 106 EV- 
producing cATMSC previously stained with NIR815) was added to 2 cm2 
scaffolds for in vivo implantation over the ischemic area of the MI 
porcine model. After 15 min of seeding and scaffold rehydration at RT, 
culture medium was added over scaffolds to promote the salt-triggered 
peptide folding and consequent self-assembling hydrogel jellification for 
a minimum of 30 min and up to 2 h at 37 ◦C before use. 
2.15. Near-infrared scaffold scanning 
To check cATMSC-EV retention in scaffolds and tracking in vivo, EV 
were produced from NIR815-labelled cATMSC. EV-associated labelling 
was confirmed by performing a dotblot assay of each SEC elution fraction 
and of the concentrated EV pool, placing 5 μl/spot by superimposing 1 μl- 
drops, and scanning for NIR815 fluorescence in an Odyssey CLx (LI-COR 
Biosciences, Inc.). Then, cATMSC-EV retention was monitored by scan-
ning NIR815-labelled EV-loaded 8-mm ∅ cardiac scaffolds in an Odyssey 
CLx, detecting the near-infrared fluorescent dye NIR815 and auto-
fluorescence in the 800-nm and 700-nm channels, respectively. To 
confirm cATMSC-EV scaffold loading right before implantation, peri-
cardial scaffolds were scanned in a Pearl Impulse Imager (Li-COR). 
2.16. Scanning electron microscopy 
To confirm cATMSC-EV presence within scaffolds, cardiac scaffolds 
loaded with NIR815-labelled EV were maintained for 1 week at 37 ◦C, 
5% CO2, after which they were washed with PBS and processed for SEM. 
Briefly, after fixation with 10% formalin (Sigma Aldrich) and washing 
with distilled water, scaffolds were dehydrated in ethanol solutions of 
increasing concentrations, and dried using a CO2 critical point dryer 
(EmiTech K850; Quorum Technologies), as detailed previously [26]. 
The scaffolds were then sputter-coated in gold using the JFC 1100 ion 
sputter (Jeol), and scanned under a JSM-6510 scanning electron mi-
croscope (Jeol) at 15 kV. 
2.17. Myocardial infarction pig model 
Animal studies were approved by the local Animal Experimentation 
Ethical Committee and Government Authorities (Generalitat de Cata-
lunya; Code:10547), and comply with the guidelines defined by the 
Guide for the Care and Use of Laboratory Animals [27]. Eight crossbreed 
Landrace x Large White pigs (31.3 ± 1.5 kg) were subjected to MI and 
randomly distributed into control (n = 4; implantation of 
hydrogel-alone filled scaffold) or treated group (n = 4; implantation of 
cATMSC-EV with hydrogel-filled scaffold). 
Animals were sedated with an intramuscular (IM) injection of atro-
pine (0.04 mg/kg; BBraun) and pre-anesthetized with dexmedetomidine 
(0.03 mg/kg, IM; Dexdor®, Orion Pharma), midazolam (0.3 mg/kg, IM; 
Laboratorios Normon), and butorphanol (0.3 mg/kg, IM; Butomidor®, 
Richter Pharma AG). Then, anaesthetic induction was performed with 
an intravenous (IV) bolus of propofol (2 mg/kg; Propovet®, Zoetis). 
Animals were endotracheally intubated, and anaesthesia was main-
tained by 2% isoflurane (IsoVet®, BBraun) inhalation. Fentanyl (0.075 
mg/kg/45 min, IV; Fentadon®, Dechra) and an IV 1.5 mg/kg atracurium 
besylate bolus (Sanofi Aventis S.A.) were administered during inter-
vention. After a left lateral thoracotomy, a double-ligation of the first 
marginal branch of the circumflex artery, 1.5 cm distally from the 
atrioventricular groove (Optilene 5/0 W-8556 12-S, Ethicon Inc.) was 
performed to induce MI. After 30 min, a pericardial scaffold, with or 
without NIR815-labelled cATMSC-EV (from 20 × 106 EV-producing 
cells), was placed over the infarcted myocardium and secured with 
0.1–0.2 mL of surgical glue (Glubran2®, Cardiolink S.L.). Tulatromicin 
(2.5 mg/kg, IM; Draxxin®, Pfizer Animal Health) was administered at 
the end of the surgery as antibiotherapy and a transdermal fentanyl 
patch was applied as an analgesic post-operative care (Durogesic®, 
Janssen-Cilag). Finally, pigs were recovered, and housed until experi-
mental end-point. 
2.18. Tissue collection, morphometric and histopathological analyses 
Six days after MI induction, animals were euthanized by adminis-
tering sodium thiopental overdose (200 mg/kg) and porcine hearts were 
excised, then scanned in a Pearl Impulse Imager (Li-COR), sectioned and 
scanned again for EV tracing within heart sections (Fig. S7). Heart 
samples, including infarct core, border zones and healthy myocardium 
were either fixed in 10% formalin for paraffin inclusion or embedded in 
OCT (VWR) and snap-frozen in liquid nitrogen-cooled isopentane. 
Descriptive histopathological analysis and scar fibrosis were ana-
lysed in 5-μm paraffin sections with Masson’s trichrome and Picrosirius 
red staining, respectively, as described previously [28]. Total collagen, 
and specifically collagen type I and III were quantified in six random 
fields of each tissue section using Image-Pro Plus software (6.2.1 
version; Media Cybernetics, Inc.). 
M. Monguió-Tortajada et al.                                                                                                                                                                                                                 
Bioactive Materials 6 (2021) 3314–3327
3318
2.19. Immunohistochemical analysis 
To examine cATMSC-EV retention within scaffolds by confocal mi-
croscopy, immunostaining was performed in PKH26-EV loaded scaf-
folds. Specifically, cardiac scaffolds with PKH26-labelled EV incubated 
for 2 h were thoroughly washed 3 times with PBS, fixed with 10% 
formalin for 1 h at RT, rinsed 3 times with PBS, embedded in OCT and 
snap-frozen in liquid nitrogen-cooled isopentane. Also, decellularisation 
was confirmed by performing immunostaining on 10-μm-thick native 
and decellularised tissue cryosections. Succinctly, after blocking for 1 h 
at RT with TBS (Tris-buffered saline)/0.2% Triton-X-100/10% horse 
serum/1% BSA (all from Sigma Aldrich), tissue sections were incubated 
overnight at 4 ◦C with phalloidin-Atto 565 (Phal565; 1:500; Sigma) and 
primary antibody against cardiac troponin I (cTnI; 1:100; Abcam) and 
type-III collagen (col-III; 1:100; Abcam). Sections were then incubated 
for 1 h at RT with Cy2-, Cy3-, and Cy5-conjugated secondary antibodies 
(1:500; Jackson ImmunoResearch Laboratories), respectively, and 
nuclei counterstained with DAPI (0.1 μg/mL; Sigma-Aldrich). 
Vascular density in the MI pig model was analysed in 10-μm OCT- 
embedded tissue cryosections immunostained with biotinylated Griffo-
nia simplicifolia Lectin I isolectinB4 (IsoB4; 1:50; Vector Labs) and 
Streptavidin-Alexa488 (1:500; Invitrogen). Macrophage, B and T cell 
infiltration was also analysed by immunostaining tissue cryosections 
using cTnI (Abcam) and CD163 (Novus Biologicals) or CD20 (Biocare 
medical), CD3 and CD25 (both from AbD Serotec) primary antibodies 
(1:100), followed by incubation with the Alexa Fluor 488-, Alexa Fluor 
647- (Molecular Probes) and Cy3- (Jackson ImmunoResearch Labora-
tories) conjugated secondary antibodies (1:500) and nuclei counter-
staining with DAPI. 
Immunofluorescence images were acquired in an Axio-Observer Z1 
confocal microscope (Zeiss). Quantitative measurements of blood vessel 
area (IsoB4 staining) in either the infarct core or scaffold were per-
formed using Image-Pro Plus software in six different random fields per 
section. Quantification of CD163+, CD20+, CD3+ and CD25+ cells, was 
carried out by two independent investigators measuring at least four 
different optical fields from each section. 
2.20. Statistical analysis 
Data is shown as mean with SD unless stated otherwise. Statistical 
differences are shown when found significant (p < 0.05) applying the 
appropriate statistical tests for each dataset after checking for normality 
of data, using Graphpad Prism (6.0 version) and SPSS 21.0.0.0 (SPSS, 
Inc, Chicago, IL) softwares. 
3. Results 
3.1. Porcine cATMSC-EV purification 
Primary cultures of porcine cATMSC were established and validated 
as positive for CD29 (84%), CD44 (88%), CD90 (99%) and CD105 (92%) 
and negative for CD14, CD34, CD45 and CD106 [7]. EV were then iso-
lated from cell- and debris-cleared conditioned media of porcine 
cATMSC cultures by SEC. cATMSC-EV were screened for EV markers 
(CD9+ CD63+ CD81low CD5Llow) and MSC markers (CD44+ CD29low 
CD73low CD90low) (Fig. S1), being CD63 and CD44 the most relevantly 
and consistently detected. Thus, they were routinely used to track 
porcine cATMSC-EV elution in the SEC fractions (Fig. 1A). Isolation by 
SEC ensured EV purification from the rest of soluble factors present in 
cATMSC conditioned media, as previously published [18]. We pooled 
the CD63+CD44+ fractions, containing porcine cATMSC-EV, and 
confirmed by cryo-EM the double membrane, round shape, and nano-
vesicle size of cATMSC-EV (Fig. 1B and C). Furthermore, EV mean 
diameter by NTA was 211.2 (14.66) nm (Fig. 1D and E), and the con-
centration of particles according to NTA was homogeneous after nor-
malisation by the EV-producing cell numbers at EV harvest (Fig. 1E). 
Protein concentration in EV pools was really low (0.554 (0.391) μg total 
protein; 6.94 × 10− 02 (7.13 × 10− 02) μg/106 cells at EV harvest), and did 
not correlate well with the EV-producing cell numbers (Fig. S2), thus it 
was not used to normalise EV numbers. Instead, we used the 
EV-producing cell numbers at harvest as a proxy of EV quantitation, as 
we and others previously reported [18,29,30]. 
Fig. 1. EV were isolated from porcine cATMSC by SEC, and phenotypical and morphologically characterised. (A) Representative SEC elution profile of porcine 
cATMSC-EV, found in the fractions positive for the EV and MSC markers CD63 and CD44 (MFI, median fluorescence intensity by bead-based flow cytometry). The 
protein eluted later, measured by BCA. (B) Cryo-EM confirmed that porcine cATMSC-EV were double membrane round nanovesicles of 50–300 nm. Scale bars are 
500 nm and 200 nm, respectively. (C) Histogram depicting the size distribution of cATMSC-EV according to cryo-EM (n = 280). (D) Representative histogram 
depicting size and concentration of EV according to NTA analysis. (E) EV diameter by NTA was around 200 nm. Concentration of particles according to NTA, 
normalised by the EV-producing cell number. 
M. Monguió-Tortajada et al.                                                                                                                                                                                                                 
Bioactive Materials 6 (2021) 3314–3327
3319
3.2. cATMSC-EV have immune suppressive properties 
To test the immunomodulatory properties of cATMSC-EV, we ana-
lysed their potency in terms of proliferation and cytokine secretion of 
allogeneic porcine PBMC modulation by the presence or absence of 
cATMSC-EV. PBMC were activated with PMA plus Io, that simulated the 
pro-inflammatory environment found in the ischemic injury post-MI, 
which led to high PBMC proliferation and an inflammatory cytokine 
response (Fig. 2). When cATMSC-EV were added to the mix, they dose- 
dependently suppressed the proliferation of allogeneic PBMC (Fig. 2A). 
Notably, the capacity of cATMSC-EV to inhibit PBMC proliferation was 
not dependent on the specific EV pool, but rather on the responder 
PBMC donor. cATMSC-EV also abrogated the secretion of the pro- 
inflammatory cytokines IFNγ, TNFα, and IL12p40 in stimulated PBMC 
(Fig. 2B). IL10 was also reduced by cATMSC-EV. However, the lowest EV 
dose maintained IL10 production while reducing the pro-inflammatory 
cytokine levels, thus increasing the IL10:IFNγ ratio. IL6 and IL8 secre-
tion was not modified by cATMSC-EV. Other cytokines, including IL1β, 
IL4, and IFNα, were found at negligible levels (<10 ng/ml) and did not 
change by cATMSC-EV presence (data not shown). Notably, the lack of 
cytokine response to cATMSC-EV from allogeneic PBMC suggested an 
absence of alloreactivity. The absence of TNFα induction, and actually 
reduction by cATMSC-EV, suggested that the EV products had low 
endotoxin levels, as corroborated by endotoxin testing (<2 EU/ml). 
Nevertheless, this is an important issue to inspect before clinical trans-
lation. EV production under GMP conditions and manufacturing in clean 
room facilities would further reduce the endotoxin levels to fulfil reg-
ulatory requirements. 
3.3. Porcine cATMSC-EV recruit allogeneic pro-regenerative cells and 
promote angiogenesis 
The success of the local delivery of EV for myocardial repair relies on 
the hypothesis that EV will recruit endogenous cells towards the 
infarcted tissue, and among other beneficial effects, promote revascu-
larisation of the injured myocardium. To start validating this hypothesis 
in vitro, we quantitatively analysed the chemotactic action of cATMSC- 
EV towards allogeneic OEC and MSC in agarose spots, using an adap-
tation of a previously described protocol [24,25], and their effect on the 
tube formation capacity of OEC. 
Swine OEC were isolated from porcine peripheral whole blood 
samples. We confirmed them as genuine hematopoietic vascular pre-
cursors with specific endothelial-lineage marker expression, such as 
VEGFR2, vWF, CD31 (immunocytofluorescence; Figs. S3A–C), and CD34 
(flow cytometry; Fig. S3D), and formed vascular-like networks when 
seeded in Matrigel (Fig. S3E). 
Then, we analysed the active migration of MSC and OEC towards 
agarose spots containing increasing doses of cATMSC-EV. While no cells 
entered the spots containing buffer alone, MSC and OEC invaded the 
spots containing cATMSC-EV in a dose-dependent manner (Fig. 3 and 
Supplementary Videos 1–6). Of note, OEC also migrated inside the spots 
containing VEGF, used as a positive control. OEC and MSC tracking over 
Fig. 2. Porcine cATMSC-EV abrogate poly-
clonal proliferation and modulate the cyto-
kine response of allogeneic PBMC. (A) Two 
representative EV pools (#1 and #2) were 
tested in potency assays (doses of 2 × 105, 1 
× 105 and 5 × 104 EV-producing cells) 
against two different fully allogeneic PBMC 
responders (1 × 105 cells) with polyclonal 
stimulation (PMA + Io; Control +). Prolif-
erating PBMC were determined according to 
dye dilution as the percentage of FSChigh-
e670low cells. Data are shown as mean ± SD. 
Statistical differences to the positive control 
(PMA + Io) are indicated as *p < 0.05; **p 
< 0.01; ***p < 0.001 by Two-way ANOVA 
with Tukey’s multiple comparison test. (B) 
We assessed the cytokine levels in superna-
tants of the two different fully allogeneic 
PBMC in the presence or absence of two 
different cATMSC-EV pools (10:1, 2:1, and 
1:1 cATMSC-EV:PBMC ratios) at five days 
after PMA + Io stimulation. Bars indicate 
mean ± SD. *p < 0.05; **p < 0.01 by one- 
way ANOVA with Dunn’s multiple compar-
ison test.   
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24 h indicated a positive directionality in the cell movement towards the 
EV-containing spots, demonstrated by an increased Directness of 
movement and Euclidean distance (Δxy) of cells, while no changes in the 
Accumulated distance (ΣΔxy) or Velocity of cells was found (data not 
shown). Also, this was only observed in OEC and MSC in contact with the 
agarose spot (border versus remotely positioned cells; Fig. 3). 
Supplementary video related to this article can be found at https:// 
doi.org/10.1016/j.bioactmat.2021.02.026 
Secondly, cATMSC-EV were able to promote angiogenesis on allo-
geneic porcine OEC in a dose-dependent manner (Fig. 4). The number of 
nodes and branch length increased with EV dose, and thickened 
vascular-like meshes were observed in the highest EV doses analysed. Of 
note, the EV concentration range was equal to that used in the prolif-
eration assays. 
3.4. Biocompatible 3D-Engineered scaffolds maintain the internal 
ultrastructure and are devoid of cells after decellularisation 
Two decellularised cardiac scaffolds were generated from either 
human pericardial or porcine myocardial tissues, with their intrinsic 
structure preserved, including the spatial 3D organization of the native 
matrix fibrils (Figs. S4A–D). Complete decellularisation was confirmed 
in both pericardium and myocardium by the absence of actin 
(Figs. S4E–F) and cardiac troponin I (Figs. S4G–H), respectively, and 
removal of cell nuclei in both acellular scaffolds (Figs. S4F and H). 
Additionally, the positive staining for type-III collagen (Figs. S4E–H), 
proved the preservation of extracellular matrix (ECM) protein compo-
nents following decellularisation, as previously described [12]. More-
over, as we previously published, a proteomic characterization of 
decellularised pericardial and myocardial scaffolds revealed the pres-
ence of matrisome/ECM-related proteins, including major cardiac ECM 
components like ECM glycoproteins and regulators, collagens and pro-
teoglycans, consistent to their corresponding native tissues [12]. 
Fig. 3. Porcine cATMSC-EV recruit allogeneic swine cATMSC and swine peripheral blood OEC. (A–C) Allogeneic cATMSC were added to plates with agarose spots 
containing increasing doses of cATMSC-EV (from 4 × 104 and 8 × 104 cells), and cell migration was assessed over 24 h. (D–F) OEC were added to plates with agarose 
spots containing VEGF (positive control) or cATMSC-EV (from 8 × 104 cells), and cell migration was assessed over 24 h. (A, D) Representative images of agarose spot 
borders (dotted line) at 0 and 24 h. Migrating cells are observed only inside spots containing EV or VEGF. Scale bars = 100 μm. (B, E) The corresponding rose plots of 
cell movement during the 24-h time-lapse. Arrow cap indicates direction to the spot. The border and remote positions were determined at 0 h for cells localised or not 
in the border of the agarose spot, respectively. (C, F) Directness and Euclidean distance (Δxy) of cell movement. Pictures were taken hourly, tracking ten cells in each 
position of at least three spot positions tracked for each condition. (A–C) N = 2 independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 by two-way 
ANOVA with Tukey’s post-hoc analysis. (D–F) N = 3 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 by two-way ANOVA 
with Tukey’s post-hoc analysis. 
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3.5. Porcine cATMSC-EV are successfully retained within 3D-Engineered 
cardiac scaffolds 
To assess the feasibility of EV delivery through confinement in 3D- 
engineered cardiac scaffolds, we first evaluated EV retention within 
the scaffolds. For that, we loaded the decellularised, lyophilised scaf-
folds with cATMSC-EV mixed with self-assembling peptide hydrogel, 
necessary to enhance scaffold rehydration and ensure filling with EV 
(Fig. S5). EV were fluorescently stained for tracking with lipophilic dyes, 
but to avoid troublesome EV washing and carry-over of lipophilic dye 
aggregates from labelled EV, the EV-producing cATMSC were labelled 
instead, enabling the tracking of fluorescently-labelled EV. NIR815 EV- 
associated labelling was confirmed by performing a dotblot of each SEC 
elution fraction, scanning fluorescence at 800 nm (Fig. 5A). The NIR815 
fluorescent signal was increased after concentrating the EV pool by 100 
kDa ultrafiltration (Fig. 5A, right). Then, the concentrated EV pool was 
mixed with self-assembling peptide hydrogel, and used to fill and 
rehydrate lyophilised pericardial and myocardial scaffolds. After the 
salt-triggered hydrogel jellification, scaffolds were thoroughly washed 
with PBS and near-infrared fluorometric scanning revealed cATMSC-EV 
retention in both 3D-bioengineered cardiac scaffolds (Fig. 5B). Note-
worthy, pericardial scaffolds held higher amounts of EV according to 
fluorescence intensity quantification and visible in the scanned images, 
observing an earlier saturation of myocardial scaffolds (Fig. 5C). Of 
Fig. 4. Porcine cATMSC-EV promote angiogenesis 
to allogeneic swine peripheral blood OEC. OEC 
were seeded in Matrigel-coated wells, with 
increasing doses of cATMSC-EV (2 × 106/ml, 1 ×
106/ml or 4 × 105/ml producing cells) or VEGF 
(200 ng/mL). (A) Representative images at 6 h, 
showing an increased number of junctions and 
thickening of the vascular-like networks with 
increasing EV doses. (B) Tube formation was 
quantified in terms of Number of nodes (top) and 
Branching length (bottom). Data includes 2 inde-
pendent experiments, each with 3 biological repli-
cates and 2 technical replicates each. **p < 0.01, 
and ***p < 0.001 and ****p < 0.0001 by One-way 
ANOVA with Tukey’s post-hoc analysis.   
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note, both scaffolds released the EV with time (Fig. S6). 
To corroborate cATMSC-EV retention inside the scaffolds, we loaded 
them with PKH26-labelled cATMSC-EV, following the same aforemen-
tioned procedure. Indeed, confocal microscope imaging of scaffold mid- 
sections revealed cATMSC-EV presence within the scaffolds (Fig. 5D). 
Moreover, even after thorough washing and a week-long culture at 
37 ◦C, cATMSC-EV were found inside the scaffolds as confirmed by SEM, 
distinguishable as 100- to 120-nm protuberances embedded in the 
hydrogel filling the scaffolds (Fig. 5E). 
3.6. Porcine cATMSC-EV combined with cardiac scaffolds abrogate the 
cytokine response of allogeneic PBMC 
To examine the immunomodulatory capacity of cATMSC-EV 
embedded in cardiac scaffolds, we studied the cytokine response of 
allogeneic PBMC, stimulated or not with PMA plus Io, and cultured with 
cardiac scaffolds filled with hydrogel alone or mixed with cATMSC-EV. 
The presence of the scaffolds themselves already weakened cytokine 
secretion by stimulated PBMC (Fig. S7), which could be attributed to 
Fig. 5. Engineered cardiac scaffolds retained cATMSC-EV, as shown by fluorometric scanning, confocal microscopy and SEM imaging. (A) Dotblot of SEC fractions 
eluting NIR815-labelled porcine cATMSC-EV, scanning fluorescence at 800 nm. EV-containing fractions (squared) were confirmed NIR815+, pooled together and 
concentrated by 100 kDa-ultrafiltration, maintaining NIR815 fluorescence (right). (B–C) NIR815-labelled cATMSC-EV mixed with peptide hydrogel and added to 
pericardial and myocardial scaffolds were detected after thorough washing of scaffolds. (B) Representative near-infrared fluorescent scanning images of pericardial 
and myocardial scaffolds (autofluorescence at 700 nm, red) embedded with NIR815-cATMSC-EV (NIR815 fluorescence at 800 nm, green). Scale bar = 1 cm. (C) 
NIR815-cATMSC-EV fluorescence quantification expressed as relative to hydrogel-alone filled scaffold (background). (D) PKH26-labelled cATMSC-EV (red) were 
detected inside the scaffolds by confocal imaging, after immunostaining for collagen III (col III; grey). Scale bar = 20 μm. (E) SEM imaging confirms retention of 
porcine cATMSC-EV within scaffolds after washing and week-long culture, appearing as 100–120 nm protuberances embedded in the hydrogel filling the scaffolds. 
Controls are scaffolds filled with peptide hydrogel alone. Scale bar = 1 μm. 
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both biological effects or to technical reasons, as scaffolds would be 
greatly hindering PBMC cell contact. There were only a few exceptions: 
IL6 and IL8 were secreted by stimulated PBMC in the presence of 
myocardial scaffolds, which was increased with cATMSC-EV, while very 
low levels of IFNγ and TNFα were found. Notably, only IL6 secretion was 
found in the presence of cATMSC-EV embedded in pericardial scaffolds, 
whereas none of the other pro-inflammatory cytokines were detected. 
Therefore, pericardial scaffold was the preferred construct to be tested in 
vivo due to its improved EV retention and low immunoreactivity. 
3.7. Locally administered porcine cATMSC-EV stay within scaffolds and 
infarct core 
To assess safety and biodistribution of the cATMSC-EV once 
administered in vivo, a study was performed using the acute MI pig 
model. Pericardial scaffolds containing NIR815-labelled cATMSC-EV 
mixed in peptide hydrogel were implanted over the ischemic area of 
treated animals, and were compared to the use of a hydrogel-alone filled 
scaffold in control animals. Fluorescent signal of scaffolds loaded with 
NIR815-cATMSC-EV was confirmed before implantation (Fig. S8). One 
animal died after ventricular fibrillation during MI induction and one 
exhibited no evidence of MI and was excluded from the final analysis, 
which included three treated and three control animals. Six days after 
implantation, porcine hearts and sections, as detailed in (Fig. S9), were 
scanned to track the presence of NIR815-labelled cATMSC-EV. They 
were detected in both the graft and infarct core, and had persisted only 
within the damaged area of treated animals (Fig. 6 and Fig. S10). 
3.8. In vivo scaffold neovascularization and reduction of macrophage and 
T cell infiltration 
All the scaffolds integrated to the myocardium, showing neo-
innervation and neovascularization regardless of EV loading (Fig. S11) 
as previously observed [13]. Nevertheless, cATMSC-EV presence 
induced greater vascular density within scaffolds (Fig. 7A–B; 0.15% 
(0.058) vs 0.93% (0.410) IsoB4 area in Control vs Treated animals; p =
0.031). Regarding the MI area, although not significant, less fibrotic area 
was observed in the infarct core (Fig. 7C; 0.46% (0.35) vs 0.13% (0.06) 
Collagen I area in Control vs Treated animals; p = 0.2). Moreover, 
treated animals had a marked decrease of infiltrating monocytes 
(CD163+) in the infarct core (Fig. 7D–E) (26.38% (2.3) vs 1.942% (2.91) 
in Control vs Treated animals; p = 0.002), whereas no differences were 
found within the scaffold itself (32.7% (9.26) vs 30.08% (12.60); p =
0.78). Regarding B cell infiltration, it was rare and no differences were 
found (Fig. 7F–G). On the other hand, the decrease in macrophages was 
accompanied with a reduction in T cell infiltration, observed in the 
infarcted tissue (Fig. 7F–G) (27.23% (7.86) vs 11.66% (0.97) in Control 
vs Treated animals; p = 0.008), but not significant in the scaffold area 
(22.61% (12.78) vs 16.66% (4.59) in Control vs Treated animals; p =
0.53). No significant differences were found either in the amount of 
CD25+ T cells. 
4. Discussion 
In the present study, we deepen into the beneficial properties of 
porcine MSC-EV isolated by SEC for reparative medicine, set up poten-
tial immunomodulatory, chemotactic and pro-angiogenic potency as-
says and unravel a new role of porcine MSC-EV as recruiters of 
endogenous pro-angiogenic cells. At the same time, we describe the 
development of a new generation of cell-free cardiac grafts comprising 
MSC-derived EV embedded with peptide hydrogels in cardiac decellu-
larised scaffolds for local myocardial delivery. 
Cardiac tissue engineering, which is based on the scaffolding of 
reparative cells and/or bioactive factors with supportive materials, is a 
potential alternative therapy to limit adverse ventricular remodelling, 
and ultimately preserve heart function post-MI [31]. In this context, 
decellularised cardiac scaffolds are a source of biological ECM derived 
from native cardiac tissues, with conserved micro- and macro-scale ECM 
structure and functional cardiac ECM composition [32,33]. Specifically, 
we already have a protocol approved by the Spanish Agency of 
Fig. 6. Porcine NIR815-cATMSC-EV detection in the scaffold and infarct area in vivo after six days post-implantation. Representative images of one treated animal are 
shown. (A, B) Anterior side of a treated pig heart six days after MI. Heart sectioning is indicated by yellow dotted line. (A) The scaffold (not visible due to the tissue 
coverage) was implanted following the coronary branch descending from the MI ligation (*). (B) Fluorescent scanning and bright field photography of the region of 
the heart indicated in (A). The NIR815-EV fluorescence (green; 800 nm) could be detected through, and despite the covering tissue, where the scaffold was 
implanted. (C) The scaffold (white dotted line) and MI area (black dotted line) can be observed in the transversal cut of the 1.5 cm-heart section spanning from the MI 
ligation to the half of the scaffold. (D) Administered NIR815-cATMSC-EV (green; 800 nm) are detected within the scaffold and MI core (red; autofluorescence; 700 
nm) by fluorescent tracking. Both fluorescent signals are overlaid on a white light image of the heart section. (E) Close-up image of the scaffold (white dotted line) 
and MI area (black dotted line). (F) Pseudo-colour intensity image depicting NIR815-EV signal at the 800 nm channel within the scaffold (black dotted line) and 
infarct core. (G) Quantification of NIR815 signal in the infarct and scaffold area. Bars indicate mean ± SD. p < 0.001 difference in the infarct core and p < 0.01 in the 
scaffold area between Control (n = 3) and Treated animals (n = 3) by Two-way ANOVA. 
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Medicines and Medical Devices (AEMPS; PEI18-140) to produce 
clinical-grade scaffolds from healthy pericardium of cadaveric donors, 
and currently being used in a clinical trial [34]. 
Following our established decellularisation methods, we obtain 
acellular cardiac constructs that can be rehydrated with aqueous peptide 
hydrogels, and repopulated with cATMSC [7,12,26] or presently, EV. In 
our previous studies, the implantation of scaffolds with cATMSC 
improved post-MI cardiac function in the preclinical swine model. 
Microscopically, the engineered grafts integrated with the underlying 
myocardium, and showed signs of neoinnervation and neo-
vascularization [10–13]. However, despite exhibiting promising results, 
it remains uncertain how the implanted cells contribute to MI recovery, 
since, as many others also report, administered cells display poor sur-
vival and engraftment, and negligible proliferation and differentiation 
within the myocardial tissue. A plausible hypothesis would be that 
instead of replacing the injured tissue themselves, cATMSC would 
reduce the ischemic injury-triggered inflammation by modulating the 
host’s immune system and foster endogenous regeneration in a para-
crine fashion. Specifically, they induce CD73 expression in M2-like 
polarised monocytes and reduce the number of activated CD4+CD25+
T cells [11,35], along with recruiting peripheral progenitor cells via 
trophic factors [15,36–39]. Based on our previous findings and the 
increasing evidence that EV play important roles in MSC’s paracrine 
effects [17,18,40], we decided to design and study a new generation of 
cell-free cardiac grafts, based on the potential of cATMSC-EV combined 
with our tissue engineering approach. Rationally, EV have several ad-
vantages over cells thanks to their unchanged phenotype, lack of 
tumorigenicity, limited immunoreactivity, and better biodistribution 
and stability. In fact, the sustained delivery of distinct EV sources using a 
variety of injectable hydrogels or engineered patches is currently under 
scrutiny [41–43]. To this end, we purified porcine cATMSC-EV by SEC, a 
stringent method that yields a pool of MSC-derived EV already proven to 
be immunomodulatory when derived from human samples [18]. 
In the present work, we show that porcine cATMSC-EV inhibit 
polyclonal activation (proliferation and pro-inflammatory cytokine 
production) of allogeneic immune cells, comparable to post-MI cir-
cumstances. Following the ischemic injury, danger-associated signals 
released by cardiomyocyte death and ECM degradation trigger an in-
flammatory reaction, including the production of inflammatory cyto-
kines (IL1β, IFNγ, TNFα and IL6) and chemokines that activate and 
recruit the innate immune system. While this initial response is crucial 
for dead cell clearance and tissue repair, its timely repression would 
prevent detrimental inflammation and amplification of the myocardial 
damage [44,45]. 
Here we report that cATMSC-EV abrogated the secretion of TNFα, a 
cytokine extensively associated to cardiac damage and worsening of 
heart failure symptoms [44]. On the other hand, IL6 and IL8 levels were 
unaltered by porcine cATMSC-EV. While IL6 production has 
Fig. 7. Porcine cATMSC-EV induce more neovascularization within the scaffold and less infiltrating macrophages in the infarct area. (A) Representative images of 
scaffold areas from a Control and Treated animals stained with Isolectin-B4 (green) showed an increase in vascular density when cATMSC-EV were loaded to the 
scaffolds. (B) Percentage of vessel area within the scaffold. (C) Percentage of collagen I area within the infarct area, assessed by Sirius Red staining. (D) Immu-
nohistofluorescence against CD163 (red), cTnI (white), and DAPI (blue) of Control and Treated animals of the infarct core show a reduced macrophage infiltration 
when cATMSC-EV were implanted with scaffolds. Arrows indicate macrophages (CD163+) found within the infarct core. (E) The number of CD163+ cells per field 
within the infarct core. *p < 0.05; **p < 0.01 by T-Student test. (F) Immunohistofluorescence against CD3 (red), CD25 (white), CD20 (green) and DAPI (blue) of 
Control and Treated animals of the infarct core show a reduced T cell infiltration when cATMSC-EV were implanted with scaffolds. Arrows indicate activated T cells 
(CD3+CD25+). (G) The number of infiltrating B cells (CD20+) and T cells (CD3+) per field and % of CD25+ T cells (CD3+) per field within the infarct core. Bars 
indicate mean ± SD corresponding to three animals per group. **p < 0.01 by Two-way ANOVA. Scale bar = 20 μm. 
M. Monguió-Tortajada et al.                                                                                                                                                                                                                 
Bioactive Materials 6 (2021) 3314–3327
3325
controversial functions in MI, it has been also related to the initiation of 
reparative processes [46–49]. As to IL8, it recruits the neutrophils 
needed after MI for clearance of dead cells and degraded ECM, and 
assisting the initiation of the inflammatory phase. However, neutrophil 
ablation does not correlate to a change in infarct size [48]. 
Regarding IFNγ and IL12, available in vivo data report Th1-polarized 
CD4+ T cells the predominantly present in the ischemic myocardium 
[50]. Moreover, experiments in RAG1 KO mice reconstituted with CD4+
T cells from either WT or IFNγ-KO mice beautifully uncovered that 
IFNγ-mediated Th1 CD4+ T cells contribute to MI injury [51,52]. Thus, it 
is encouraging that cATMSC-EV suppress the production of IFNγ and the 
Th1-driving IL12, translating in a decrease on T cell infiltration in vivo. 
Finally, the known interferon- and IL12-dependent IL10 production 
might explain its concomitant reduction in our experiments [53,54]. 
Moreover, there could be other immunoregulatory mediators playing a 
role besides IL10 that have not been studied. In summary, the decrease 
in pro-inflammatory cytokines evidences the powerful immune modu-
latory effect of cATMSC-EV towards allogeneic polyclonal activation. 
The exploratory in vitro experiments incorporating scaffolds to 
stimulated PBMC proved difficult to interpret, as the mere presence of 
the unloaded scaffolds already disrupted cytokine production, likely due 
to minimized cell interaction. Unexpectedly, cATMSC-EV addition to 
either type of scaffold spiked IL6 production. Although we do not have a 
clear explanation for this phenomenon, and we cannot affirm whether 
this also happens in vivo, it did not translate into an adverse reaction 
after in vivo scaffold implantation. Individually, only cATMSC-EV com-
bined with myocardial scaffolds increased IFNγ, TNFα, and IL8, 
although still in less amounts than stimulated PBMC alone. On the other 
hand, and despite being of human origin, pericardial scaffolds did not 
induce such cytokine response, suggesting absence of xenoreactivity. 
Moreover, pericardial scaffolds seemed to retain multifunctional 
cATMSC-EV in a larger extent in comparison with myocardial scaffolds. 
Along this line, the bigger caveats of pericardial scaffolds already dis-
played better cell penetrance and retention. Other differences regarding 
EV or immune interaction could be explained by the different 
biochemical composition, variations in signalling ligands between the 
two scaffolds [12]. These findings support our downstream 
proof-of-concept in vivo experiments combining cATMSC-EV with peri-
cardial scaffolds. 
This EV delivery strategy aims at magnifying the local effective dose 
of administered EV, thus downsizing the required EV units and side 
targets. In fact, fluorescence-aided tracking of EV showed the confine-
ment and slow release of EV within scaffolds, even once implanted. 
Interestingly, fluorescent signal could be also found within the infarct 
core, indicating that either cATMSC-EV were present there, or that cells 
that interacted with EV -and therefore acquired the dye-were later on 
migrating towards the MI area. Also, the combination of EV with tissue 
engineering, such as injectable ECM hydrogels, allows a prolonged 
release of its embedded EV instead of rapid diffusion, and protect EV 
from degradation [42,43,55]. 
cATMSC-EV showed immune suppressive properties and, for the first 
time to our knowledge, we provide evidence of MSC-EV-mediated 
directed recruitment of allogeneic pro-regenerative cells, including 
allogeneic MSC and peripheral blood-derived OEC in vitro. This 
concurred with angiogenesis promotion in vitro and translated to an 
enhanced on-site neovasculogenesis in vivo, an essential first step to 
trigger endogenous cardiac repair. The power of EV-mediated recruit-
ment was shown by De la Fuente and colleagues, using tumour-derived 
EV as bait to successfully attract and encapsulate circulating metastatic 
cells to an artificial 3D scaffold and enable their localised surgical 
removal [56]. In addition, EV can bear functional chemokines attached 
to surface [57], enabling recognition by cells. Ahmed and colleagues 
demonstrated that a concentration gradient is established across and 
within the agarose spot (in their case, purified chemokines), leading to 
cell recruitment towards the centre of the spot of cells in close contact 
with the spot, while cells in a remote position have a stochastic 
movement and do not respond to the chemokines stimuli [24]. In line, 
our experiments indicate that cells are indeed sensing chemoattractant 
molecules present in EV, as only the OEC and MSC in contact with 
cATMSC-EV were attracted towards them. 
On the other side, the administration of cATMSC-EV greatly reduced 
the number of infiltrating monocytes and T cells in the MI core six days 
after MI induction, which would correlate with the anti-inflammatory 
properties of cATMSC-EV observed in vitro. Within this relatively short 
time span monocytes are known to be found in great numbers in the 
post-ischemic myocardium, and recent studies suggest that infiltrating 
monocytes are responsible of exacerbating the inflammatory milieu 
post-MI that further deteriorates myocardial tissue [58–60]. Notably, 
although the percentage of CD25+ T cells was unchanged, the overall 
number of T cells within the damaged MI tissue decreased. Thus, this 
marked change in infiltrating immune cells induced by MSC-EV could be 
indicative of the promotion of a shift from the inflammatory towards a 
regenerative phase, something that merits further investigation in 
longer time points. Of note, infiltration within the scaffold was low and 
did not change with cATMSC-EV, indicating the lack of immune 
reactivity. 
Finally, with clinical translation in mind, it would be interesting to 
study the bioequivalence of cATMSC-EV and EV derived from other 
sources of human MSC-EV, such as umbilical cord, with better avail-
ability, less ethical concerns and less epigenetic/environmental 
imprinting than adult sources of MSCs. 
In summary, our data support the potential of multifunctional 
cATMSC-EV combined with biocompatible cardiac scaffolds generated 
by decellularisation of human pericardium for effective local delivery 
over post-infarcted myocardial tissue. Moreover, SEC is a valuable 
method to obtain highly purified MSC-EV with functional properties 
reciprocal to their parental MSC [18,61]. Noticeably, we find MSC-EV to 
be anti-inflammatory, as well as able to recruit pro-regenerative cells 
and promote angiogenesis in vivo. Hence, MSC-EV delivery into 
post-infarcted myocardium presumably generates a highly bioactive 
niche that triggers endogeneous cardiac repair. Nonetheless, further 
studies are mandatory to corroborate the effectiveness of this cell-free 
tissue engineering approach to benefit cardiac healing and ultimately 
improve cardiac function in the long-term. 
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Yáñez-Mó (Dept Biología Molecular, UAM; Centro de Biología Molecular 
Severo Ochoa (CBM-SO), Hospital Universitario de la Princesa (IIS-IP)) 
and Dr. Francisco Sánchez-Madrid (Servicio de Inmunología, IIS-IP, 
UAM; Centro Nacional de Investigaciones Cardiovasculares (CNIC)) 
for antibody donations, and to Dr. Hernando A. del Portillo (ICREA 
Research Professor at ISGLOBAL-IGTP) for access to NTA instrument. 
Abbreviations 
BSA bovine serum albumin 
cATMSC cardiac adipose tissue-derived MSC 
CCM concentrated conditioned medium 
cryo-EM cryo-electron microscopy 
DAPI 4′,6-diamidino-2-phenylindole 
EBM-2 endothelial cell basal medium-2 
ECM extracellular matrix 
EGM-2 endothelial growth medium-2 
EV extracellular vesicles 
FBS foetal bovine serum 
hEGF human endothelial growth factor 




MFI median fluorescence intensity 
MI myocardial infarction 
MSC mesenchymal stromal cell 
OEC outgrowth endothelial cell 
PBS phosphate-buffered saline 
PBMC peripheral blood mononuclear cells 
PMA phorbol 12-myristate 13-acetate 
P/S penicillin-streptomycin 
RT room temperature 
SEC size exclusion chromatography 
SEM scanning electron microscopy 
3D three-dimensional 
TBS tris-buffered saline 
T-PBS Tween-PBS 
UC ultracentrifugation 
VEGF vascular endothelial growth factor 
Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.bioactmat.2021.02.026. 
References 
[1] World Health Organization, Global Health Estimates 2016: Deaths by Cause, Age, 
Sex, by Country and by Region, 2000-2016, 2018. 
[2] G. Olivetti, J.M. Capasso, L.G. Meggs, et al., Cellular basis of chronic ventricular 
remodeling after myocardial infarction in rats, Circ. Res. 68 (1991) 856–869, 
https://doi.org/10.1161/01.RES.68.3.856. 
[3] M. Metra, P. Ponikowski, K. Dickstein, et al., Advanced chronic heart failure: a 
position statement from the study group on advanced heart failure of the heart 
failure association of the European society of cardiology, Eur. J. Heart Fail. 9 
(2007) 684–694. 
[4] M.C. Alraies, P. Eckman, Adult heart transplant: indications and outcomes, 
J. Thorac. Dis. 6 (2014) 1120–1128, https://doi.org/10.3978/j.issn.2072- 
1439.2014.06.44. 
[5] M.W. Curtis, B. Russell, Cardiac tissue engineering, J. Cardiovasc. Nurs. 24 (2009) 
87–92, https://doi.org/10.1097/01.JCN.0000343562.06614.49. 
[6] A. Bayes-Genis, C. Soler-Botija, J. Farré, et al., Human progenitor cells derived 
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[25] A. Calle, C. Barrajón-Masa, E. Gómez-Fidalgo, et al., Iberian pig mesenchymal 
stem/stromal cells from dermal skin, abdominal and subcutaneous adipose tissues, 
and peripheral blood: in vitro characterization and migratory properties in 
inflammation, Stem Cell Res. Ther. 9 (2018) 178, https://doi.org/10.1186/ 
s13287-018-0933-y. 
[26] I. Perea-Gil, J.J. Uriarte, C. Prat-Vidal, et al., In vitro comparative study of two 
decellularization protocols in search of an optimal myocardial scaffold for 
recellularization, Am. J. Transl. Res. 7 (2015) 558–573. 
[27] NIH, Guide for the Care and Use of Laboratory Animals, eighth ed., National 
Academies Press, Washington, D.C, 2011. 
[28] C. Gálvez-Montón, C. Prat-Vidal, S. Roura, et al., Transposition of a pericardial- 
derived vascular adipose flap for myocardial salvage after infarct, Cardiovasc. Res. 
91 (2011) 659–667, https://doi.org/10.1093/cvr/cvr136. 
[29] L. Kordelas, V. Rebmann, A.K. Ludwig, et al., MSC-derived exosomes: a novel tool 
to treat therapy-refractory graft-versus-host disease, Leukemia 28 (2014) 970–973. 
[30] M. Tkach, J. Kowal, A.E. Zucchetti, et al., Qualitative differences in T-cell 
activation by dendritic cell-derived extracellular vesicle subtypes, EMBO J. 36 
(2017) 3012–3028, https://doi.org/10.15252/embj.201696003. 
[31] C. Gálvez-Montón, C. Prat-Vidal, S. Roura, et al., Update: innovation in cardiology 
(IV). Cardiac tissue engineering and the bioartificial heart, Rev. Esp. Cardiol. 66 
(2013) 391–399, https://doi.org/10.1016/j.rec.2012.11.012. 
[32] P.M. Crapo, T.W. Gilbert, S.F. Badylak, An overview of tissue and whole organ 
decellularization processes, Biomaterials 32 (2011) 3233–3243, https://doi.org/ 
10.1016/j.biomaterials.2011.01.057. 
[33] D.A. Taylor, L.C. Sampaio, Z. Ferdous, et al., Decellularized matrices in 
regenerative medicine, Acta Biomater. (2018), https://doi.org/10.1016/j. 
actbio.2018.04.044. 
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